Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy

[1]  R. Motzer,et al.  Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Belldegrun,et al.  Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial , 2017, JAMA oncology.

[3]  R. Motzer,et al.  Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). , 2017 .

[4]  K. Bensalah,et al.  European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma , 2016 .

[5]  Lynne Penberthy,et al.  Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992–2013 , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[6]  J. Patard,et al.  Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. , 2016, The New England journal of medicine.

[7]  E. Plimack,et al.  Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. , 2016, The Lancet. Oncology.

[8]  J. Manola,et al.  Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial , 2016, The Lancet.

[9]  C. Stief,et al.  Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  Hugh J. Lavery,et al.  Decreasing Rates of Lymph Node Dissection During Radical Nephrectomy for Renal Cell Carcinoma , 2012, Annals of Surgical Oncology.

[11]  J. Patard,et al.  Lymph node dissection in renal cell carcinoma. , 2011, European urology.

[12]  Pierre I Karakiewicz,et al.  Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. , 2011, European urology.

[13]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[14]  K. Bensalah,et al.  Stage‐specific effect of nodal metastases on survival in patients with non‐metastatic renal cell carcinoma , 2009, BJU international.

[15]  J. Cheville,et al.  Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. , 2007, The Journal of urology.

[16]  J. Patard,et al.  Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Cheville,et al.  A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. , 2003, The Journal of urology.

[18]  R. Figlin,et al.  Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Cheville,et al.  An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. , 2002, The Journal of urology.

[20]  S W Lagakos,et al.  Nonparametric estimation of lifetime and disease onset distributions from incomplete observations. , 1982, Biometrics.

[21]  M. Gordon.  Age, Tumor Size and Relative Survival of Patients With Localized Renal Cell Carcinoma: A Surveillance, Epidemiology and End Results Analysis , 2009 .

[22]  R. Gill.  Understanding Cox's regression model. , 1982, Experientia. Supplementum.